We thank Sauerbrei and Haeussler^[@CR1]^ for their interest in our paper^[@CR2]^ and their methodological comments. Our aim was to undertake these analyses and draw some conclusions from the available literature regarding the prognostic significance of BAG-1 in breast cancer, given multiple studies. We felt that this was important, particularly since BAG-1 is already included in multi-gene assays widely used as part of routine clinical practice and due to ongoing investigation into the possibility of inhibition of BAG-1 function as a potential therapeutic strategy. We did not use the supplementary information provided within the REMARK Explanation and Elaboration paper.^[@CR3]^ We provided our interpretation whether details within the REMARK checklist were included in the papers and, as we highlighted, the literature reviewed was heterogeneous and with a range in study quality. We believe our conclusions were drawn with appropriate caveats to highlight this.
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